John M. Pagel, MD, PhD

As developments in treatment options advance in chronic lymphocytic leukemia, Dr Pagel discusses the importance of finding a treatment for patients to deliver long-term outcomes that do not compromise tolerability.

The combination of zanubrutinib and zandelisib for the treatment of B-cell malignancies may offer patients the opportunity to receive therapy that is not based around chemotherapy.

Zanubrutinib and zandelisib combination appears to be a well-tolerated regimen for the treatment of B-cell malignancies, according to early study results.

Patients with relapsed or regractory B-cell malignancies who were treated with zanubrutinib and zandelisib demonstrated high response rates across several treatment cohorts.

Patients with relapsed/refractory B-cell malignancies may potentially benefit from the combination of zandelisib and zanubrutinib.

The Swedish Cancer Center expert discussed the addition of polatuzumab vedotin to a bendamustine-rituximab regimen at the ASH Annual Meeting & Exposition.